Skip to content

A Prospective Cohort Study on Familial Hypercholesterolemia in Health Examination Population

A Prospective Cohort Study on Familial Hypercholesterolemia in Health Examination Population

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04958629
Enrollment
318
Registered
2021-07-12
Start date
2021-10-01
Completion date
2023-12-31
Last updated
2021-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Familial Hypercholesterolemia

Keywords

familial hypercholesterolemia, prognosis

Brief summary

To determine the prevalence and the prognosis in a corhort of patients with familial hypercholesterolemia (FH).

Detailed description

This study aims to achieve the following goals through prospective cohort study and statistical analysis: (1) to determine the prevalence of familial hypercholesterolemia (FH) in healthy people with hypercholesterolemia.(2) Compared with non FH population, the relative risk of atherosclerotic cardiovascular disease (ASCVD) in FH patients in China was calculated, and the risk prediction model of ASCVD in FH patients was constructed by using biochemical results, imaging data, biomarkers and other indicators.(3) To evaluate the benefits of different lipid-lowering strategies for FH patients in China.(4) To analyze the gene carriers of FH patients in China.

Interventions

OTHERfamilial hypercholesterolemia

Among the selected patients with hyperlipidemia, those who met the diagnostic criteria of FH were included in the study cohort as FH group.

Sponsors

Peking University Third Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1\) Patients with definite diagnosis of hyperlipidemia.

Exclusion criteria

1. Age \< 18. 2. Do not agree to participate in this study. 3. secondary hypercholesterolemia. 4. Phytosteronemia.

Design outcomes

Primary

MeasureTime frameDescription
Number of participants with atherosclerotic cardiovascular disease (ASCVD) events2 years from enrollmet1\) Fatal or non-fatal myocardial infarction; 2) Fatal or non-fatal ischemic stroke; 3) Coronary artery revascularization; 4) Peripheral artery revascularization; 5) Cardiogenic death

Contacts

Primary ContactWei Gao, Doctor
weigao@bjmu.edu.cn+86 13901366179

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026